NASDAQ:GILD - Gilead Sciences Stock Price, Price Target & More

Question 1

What is Gilead Sciences' stock symbol?

Answer

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Question 2

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Answer

Gilead Sciences announced a quarterly dividend on Tuesday, May 1st. Shareholders of record on Friday, June 15th will be paid a dividend of $0.57 per share on Thursday, June 28th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date of this dividend is Thursday, June 14th. View Gilead Sciences' Dividend History.

Question 3

How were Gilead Sciences' earnings last quarter?

Answer

Gilead Sciences, Inc. (NASDAQ:GILD) posted its earnings results on Tuesday, May, 1st. The biopharmaceutical company reported $1.48 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.67 by $0.19. The biopharmaceutical company had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.40 billion. Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The company's revenue for the quarter was down 21.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.23 earnings per share. View Gilead Sciences' Earnings History.

Question 4

When is Gilead Sciences' next earnings date?

Answer

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Gilead Sciences.

Question 5

What price target have analysts set for GILD?

Answer

25 brokerages have issued 12-month price objectives for Gilead Sciences' stock. Their forecasts range from $72.00 to $105.00. On average, they anticipate Gilead Sciences' share price to reach $88.2271 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price. View Analyst Ratings for Gilead Sciences.

Question 6

What is the consensus analysts' recommendation for Gilead Sciences?

Answer

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 9 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."

Question 7

What are Wall Street analysts saying about Gilead Sciences stock?

Answer

Here are some recent quotes from research analysts about Gilead Sciences stock:

1. According to Zacks Investment Research, "Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy to drive growth. The HIV franchise maintains momentum driven by the rapid adoption of Descovy-based regimens. The FDA approval of Biktarvy has further widened the portfolio. Biktarvy has also been approved in Europe which should boost sales further. The initial uptake of Yescarta is encouraging in the United States and the CHMP gave a positive opinion on the same. Meanwhile, Gilead is intending to foray into the NASH market with selonsertib and filgotinib. Both the candidates are being evaluated in late stage studies and a tentative approval will diversify Gilead’s portfolio. Shares have outperformed the industry in the year so far. Estimates for Q2 are up by two cents in the last thirty days ahead of the results (scheduled for July 25). However, Gilead’s HCV franchise is under pressure due to competitive and pricing pressure." (7/18/2018)
2. Needham & Company LLC analysts commented, "Gilead reported $5.09B 1Q18 total revenue, below our $5.52B and consensus $5.3B ests. Product sales were $5.00B, below our $5.41B est. Gilead continues to lose share to Abbvie in HCV. Trend is worrisome, although mgmt still guiding for market share stabilization mid-2018. HIV sales in 1Q18 also disappointed, reportedly driven by bigger than expected seasonal inventory draw-down and generic TDF. Growth in HIV (i.e. Biktarvy success) is critical. NASH program has not yet distinguished itself, awaiting data from selonsertib Phase 3 trials (1H19) and 48wk combination Phase 2 trials (2020). Yescarta and cell therapy programs are in early stages." (5/2/2018)
3. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)
4. BMO Capital Markets analysts commented, "Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars." (2/7/2018)

Question 8

Are investors shorting Gilead Sciences?

Answer

Gilead Sciences saw a drop in short interest in June. As of June 29th, there was short interest totalling 13,703,362 shares, a drop of 16.0% from the June 15th total of 16,306,232 shares. Based on an average daily volume of 6,622,004 shares, the days-to-cover ratio is presently 2.1 days. Approximately 1.1% of the shares of the stock are short sold. View Gilead Sciences' Current Options Chain.

Question 9

Who are some of Gilead Sciences' key competitors?

Answer

Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), argenx (ARGX), Crispr Therapeutics (CRSP) and Aerie Pharmaceuticals (AERI).

Question 10

Who are Gilead Sciences' key executives?

Answer

Gilead Sciences' management team includes the folowing people:

John F. Milligan, President, Chief Executive Officer & Director
Robin L. Washington, CFO, Principal Accounting Officer & Executive VP
Andrew Cheng, Chief Medical Officer & Executive Vice President
John G. McHutchison, Chief Scientific Officer
Brett A. Pletcher, Secretary, Chief Compliance Officer & Executive VP

Question 11

Has Gilead Sciences been receiving favorable news coverage?

Answer

Media coverage about GILD stock has trended somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Gilead Sciences earned a media sentiment score of 0.19 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 44.70 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Question 12

Who are Gilead Sciences' major shareholders?

Answer

Gilead Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Swedbank (0.15%), Confluence Investment Management LLC (0.09%), Retirement Systems of Alabama (0.08%), NN Investment Partners Holdings N.V. (0.07%), Gateway Investment Advisers LLC (0.06%) and Fisher Asset Management LLC (0.04%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Question 13

Which major investors are selling Gilead Sciences stock?

Answer

GILD stock was sold by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc., Howard Capital Management Inc., JLB & Associates Inc., Hartford Investment Management Co., Nippon Life Global Investors Americas Inc., Nisa Investment Advisors LLC, Municipal Employees Retirement System of Michigan and Huntington National Bank. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Question 14

Which major investors are buying Gilead Sciences stock?

Answer

GILD stock was acquired by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Assenagon Asset Management S.A., Addenda Capital Inc., Columbus Macro LLC, State of Alaska Department of Revenue, Fisher Asset Management LLC, Manning & Napier Group LLC and IFM Investors Pty Ltd. View Insider Buying and Selling for Gilead Sciences.

Question 15

How do I buy shares of Gilead Sciences?

Answer

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

Question 16

What is Gilead Sciences' stock price today?

Answer

One share of GILD stock can currently be purchased for approximately $77.05.

Question 17

How big of a company is Gilead Sciences?

Answer

Gilead Sciences has a market capitalization of $100.38 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

Question 18

How can I contact Gilead Sciences?

Answer

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

Community Ranking:		3.6 out of 5 ( )
Outperform Votes:		1,772 (Vote Outperform)
Underperform Votes:		703 (Vote Underperform)
Total Votes:		2,475

NASDAQ:GILD - Gilead Sciences Stock Price, Price Target & More

Receive GILD News and Ratings via Email

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions